Ascendis Pharma A (ASND) Accounts Payables (2016 - 2026)

Ascendis Pharma A has disclosed Accounts Payables across 11 years of filings, most recently posting $92.0 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $92.0 million, up 3.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.0 million (up 3.67% YoY), and the FY2025 annual result was $105.5 million, up 2.45% from the prior year.
• Accounts Payables came in at $92.0 million for Q1 2026 at Ascendis Pharma A, down from $105.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $141.1 million in Q1 2023 to a low of $79.3 million in Q1 2022.
• The 5-year median for Accounts Payables is $102.7 million (2024), against an average of $102.2 million.
• Across the five-year window, Accounts Payables jumped 77.84% in 2023 and slumped 37.53% in 2024, its largest moves.
• Ascendis Pharma A's Accounts Payables stood at $103.1 million in 2022, then declined by 1.29% to $101.7 million in 2023, then increased by 1.24% to $103.0 million in 2024, then rose by 2.45% to $105.5 million in 2025, then fell by 12.81% to $92.0 million in 2026.
• The last three Accounts Payables figures came in at $92.0 million (Q1 2026), $105.5 million (Q4 2025), and $91.9 million (Q3 2025), per Business Quant data.